For research and educational purposes only. Not intended for human consumption.
Cerebrolysin
Well Researched- •Stroke recovery clinical data consolidated
- •TBI (traumatic brain injury) research updates
- •BDNF/NGF mimetic mechanism characterized
Neuropeptide Preparation | Neurological Recovery
Overview
What is Cerebrolysin?
Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.
Key Benefits
Direct brain delivery, standardized dosing, extensive clinical evidence, ready-to-use formulation.
Mechanism of Action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors that mimic BDNF and NGF activity.
Molecular Information
Pharmacokinetics
Research Indications
Alzheimer's Disease
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Vascular Dementia
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Post-Stroke Cognitive Recovery
Large meta-analysis shows significant NIHSS improvements.
Research Protocols
Disclaimer: Cerebrolysin is used clinically in over 50 countries but is not approved in the USA. These protocols are based on clinical research.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular (Lower Doses) | Up to 5mL | Once daily | Undiluted IM injection |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Timing: Start as soon as possible for acute conditions (stroke/TBI). Chronic conditions use 5-day weekly schedules. Administer in morning when possible.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Break ampoule and extract Cerebrolysin contents immediately before use
For direct injection: Up to 10mL IV undiluted (slow over 3 minutes) or up to 5mL IM
For infusion: Dilute 10-50mL to minimum 100mL total volume with compatible solution
Start infusion immediately after dilution - infuse within 15 minutes
Flush IV catheter with sodium chloride solution before and after administration
Use disposable one-way infusion sets - discard after use
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear amber solution
Cerebrolysin should be clear amber colored without particles.
Room temperature storage ≤25°C
Store at room temperature per official prescribing information.
Protected from light
Stored in original carton to protect from light exposure.
Research quality considerations
Some published studies have been retracted due to research misconduct.
Frozen product
Never freeze Cerebrolysin - freezing damages peptide structure.
Mixing with incompatible solutions
Do not mix with amino acids, vitamins, or cardiovascular medications.
What to Expect
- •Week 1-2: Initial neuroprotective effects, possible mild side effects
- •Week 2-4: Neurological improvements become apparent
- •Week 4-8: Continued recovery, motor function improvements in stroke/TBI
- •Week 8-12: Sustained benefits, cognitive enhancement plateaus
Side Effects & Safety
Side Effects
- •Monitor for allergic reactions during first administration
- •Contraindicated in epilepsy and severe renal insufficiency
- •Clinical evidence shows mixed results in some studies
- •Research integrity concerns have been raised about some published studies
- •Not approved in USA but used clinically in over 50 countries
- •Use disposable one-way infusion sets
When to Stop
- •Signs of allergic reaction
- •Seizure activity
- •Severe renal issues
- •As directed by healthcare provider
References
3 StudiesTBI Systematic Review (2023)
Human | 10-50mL daily | Variable duration | GCS/GOS improvements
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant improvements.
CAPTAIN II Trial (2020)
Human | 30-50mL daily | 10-28 days | Significant neurological improvement
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI.
Subarachnoid Hemorrhage Pilot (2020)
Human | 30mL daily | 14 days | 76% vs 48% favorable outcomes
First randomized trial in SAH patients showing promising results.
Quick Start Guide
Research Disclaimer
Cerebrolysin is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Cerebrolysin must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Cerebrolysin for any purpose. Consult qualified professionals for any research applications.